Literature DB >> 22525700

Neuroplastic changes in depression: a role for the immune system.

Harris Eyre1, Bernhard T Baune.   

Abstract

Accumulating evidence suggests that there is a rich cross-talk between the neuroimmune system and neuroplasticity mechanisms under both physiological conditions and pathophysiological conditions in depression. Anti-neuroplastic changes which occur in depression include a decrease in proliferation of neural stem cells (NSCs), decreased survival of neuroblasts and immature neurons, impaired neurocircuitry (cortical-striatal-limbic circuits), reduced levels of neurotrophins, reduced spine density and dendritic retraction. Since both humoral and cellular immune factors have been implicated in neuroplastic processes, in this review we present a model suggesting that neuroplastic processes in depression are mediated through various neuroimmune mechanisms. The review puts forward a model in that both humoral and cellular neuroimmune factors are involved with impairing neuroplasticity under pathophysiological conditions such as depression. Specifically, neuroimmune factors including interleukin (IL)-1, IL-6, tumour necrosis factor (TNF)-α, CD4⁺CD25⁺T regulatory cells (T reg), self-specific CD4⁺T cells, monocyte-derived macrophages, microglia and astrocytes are shown to be vital to processes of neuroplasticity such as long-term potentiation (LTP), NSC survival, synaptic branching, neurotrophin regulation and neurogenesis. In rodent models of depression, IL-1, IL-6 and TNF are associated with reduced hippocampal neurogenesis; mechanisms which are associated with this include the stress-activated protein kinase (SAPK)/Janus Kinase (JNK) pathway, hypoxia-inducible factors (HIF)-1α, JAK-Signal Transducer and Activator of Transcription (STAT) pathway, mitogen-activated protein kinase (MAPK)/cAMP responsive element binding protein (CREB) pathway, Ras-MAPK, PI-3 kinase, IKK/nuclear factor (NF)-κB and TGFβ activated kinase-1 (TAK-1). Neuroimmunological mechanisms have an active role in the neuroplastic changes associated with depression. Since therapies in depression, including antidepressants (AD), omega-3 polyunsaturated fatty acids (PUFAs) and physical activity exert neuroplasticity-enhancing effects potentially mediated by neuroimmune mechanisms, the immune system might serve as a promising target for interventions in depression.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525700     DOI: 10.1016/j.psyneuen.2012.03.019

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  90 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 2.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

3.  A meta-analysis of chemokines in major depression.

Authors:  Harris A Eyre; Tracy Air; Alyssa Pradhan; James Johnston; Helen Lavretsky; Michael J Stuart; Bernhard T Baune
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-02-20       Impact factor: 5.067

4.  Gene expression in major depressive disorder.

Authors:  R Jansen; B W J H Penninx; V Madar; K Xia; Y Milaneschi; J J Hottenga; A R Hammerschlag; A Beekman; N van der Wee; J H Smit; A I Brooks; J Tischfield; D Posthuma; R Schoevers; G van Grootheest; G Willemsen; E J de Geus; D I Boomsma; F A Wright; F Zou; W Sun; P F Sullivan
Journal:  Mol Psychiatry       Date:  2015-05-26       Impact factor: 15.992

Review 5.  Neuroimmune signaling: a key component of alcohol abuse.

Authors:  Jody Mayfield; Laura Ferguson; R Adron Harris
Journal:  Curr Opin Neurobiol       Date:  2013-02-22       Impact factor: 6.627

6.  Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study.

Authors:  Harris Eyre; Prabha Siddarth; Natalie Cyr; Hongyu Yang; Steve Cole; Malcolm Forbes; Helen Lavretsky
Journal:  Pharmacopsychiatry       Date:  2017-04-25       Impact factor: 5.788

7.  Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior.

Authors:  Eric S Wohleb; Jenna M Patterson; Vikram Sharma; Ning Quan; Jonathan P Godbout; John F Sheridan
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

Review 8.  The immunology of bipolar disorder.

Authors:  Izabela Guimarães Barbosa; Rodrigo Machado-Vieira; Jair C Soares; Antonio L Teixeira
Journal:  Neuroimmunomodulation       Date:  2014-02-14       Impact factor: 2.492

9.  Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression.

Authors:  H A Eyre; H Lavretsky; J Kartika; A Qassim; B T Baune
Journal:  Pharmacopsychiatry       Date:  2016-03-07       Impact factor: 5.788

10.  Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples.

Authors:  Stefano Porcelli; Raffaele Salfi; Antonis Politis; Anna Rita Atti; Diego Albani; Armando Chierchia; Letizia Polito; Aikaterini Zisaki; Christina Piperi; Ioannis Liappas; Siegfried Alberti; Martina Balestri; Agnese Marsano; Evangelia Stamouli; Antonis Mailis; Gloria Biella; Gianluigi Forloni; Virginia Bernabei; Barbara Ferrari; Loredana Lia; George N Papadimitriou; Diana De Ronchi; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2013-05-28       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.